Previous 10 | Next 10 |
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with ge...
REDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with ge...
Biomea Fusion (NASDAQ:BMEA) has been added to the NASDAQ Biotechnology Index, effective prior to market open on December 20, 2021. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasonin...
REDWOOD CITY, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with ge...
REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with ge...
BMF-219 displays global disruption of menin, highlighting ‘219’s novel mechanism of action Molecule elicits broad impact on the complexes surrounding menin, resulting in strong modulation of MYC expression, highlighting potential in multiple cancer types BMF-219 de...
Biomea Fusion (NASDAQ:BMEA): Q3 GAAP EPS of -$0.43 misses by $0.03. As of September 30, 2021, the Company had cash, cash equivalents, restricted cash, and investments of $191.9 million. Press Release For further details see: Biomea Fusion EPS misses by $0.03
Announced FDA clearance of Investigational New Drug Application (IND) for BMF-219, the company’s first development candidate from the FUSION platform Phase I trial to enroll adult patients with relapsed or refractory acute leukemia, including those with an MLL/KMT2A gene rearra...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Excerpts of this article were originally published on October 4 and 18, 2021, as part of Tom Yeung’s Moonshot Investor series. Investors interested in finding stocks with 100x potential or more can subscribe to Tom...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Insider Trading Galore On Monday, I introduced “The Inside Track” strategy, a trading system triggered by unusual insider buying. Source: Chad McDermott / Shutterstock.com The logic is deceptively si...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information...